Tuesday, October 4, 2022
News
NEWS HOME
»
PRN INDIA
FRONTIER BIOTECHNOLOGIES ANNOUNCES POSITIVE PHASE 1 RESULTS OF ITS FIRST CORONAVIRUS MAIN PROTEASE (MPRO) SMALL MOLECULE INHIBITOR, LAYING FOUNDATION FOR THE TREATMENT OF ACUTE AND LONG COVID
  SocialTwist Tell-a-Friend  
   

  • FB2001 (Bofutrelvir) is a Coronavirus Mpro inhibitor, which exhibited potent anti-SARS-CoV-2 activity in vitro and in vivo
  • Phase 1 results show FB2001 to be generally safe and well tolerated. No significant difference was observed between Chinese and American populations. Single-agent antiviral concentrations have been reached in the blood plasma and lung tissues without the need for pharmacokinetic enhancer, thus potentially minimizing the risk of drug interactions
  • It significantly reduces coronavirus viral load in the lungs and brain of a murine model, the latter which may have clinical implications for the sequelae of the central nervous system of COVID-19. FB2001 is the first anti-COVID-19 drug to report antiviral activity in the brain
  • The BRIGHT (Bofutrelvir in Global Hospitalized Patients) study, a Phase 2/3 trial that explores the utility of FB2001 in reducing the time to recovery in patients hospitalized due to COVID-19 has begun

ATLANTA, Aug. 8, 2022 /PRNewswire/ --    Frontier Biotechnologies, a biopharmaceutical company focused on the discovery, development and dissemination of innovative medicines that improve patient health, announced positive results from the Phase 1 clinical trial of its drug candidate, FB2001 – a small molecule inhibitor of coronavirus main protease (Mpro) – in healthy adult volunteers.

The data, presented today at the poster session of the 11th International Conference on Emerging Infectious Diseases (ICEID), showed FB2001 to be safe and well tolerated among trial participants. Adverse events reported during the trial were mostly mild-to-moderate in severity, with no significant differences observed between participants in the Chinese and American study centers.

"We are pleased by the positive results from FB2001's phase 1 trial. It is a significant milestone for us and the healthcare community", said Dr CJ Wang, Chief Executive Officer of Frontier Biotechnologies. "This promising result will spur us on to strive for success in later-stage trials. We believe that the work done at Frontier Biotech can elevate our efforts in the fight against COVID-19 in China and abroad."  

A total of 120 participants (80 Whites in the US and 40 Chinese in China) received intravenous infusions of FB2001 at either single doses from 5 mg to 400 mg, or multiple doses of 30 mg to 400 mg daily for 5 days. The key findings from the study are as follows:

  • FB2001 was safe and well tolerated up to 400 mg per day
  • Without using a pharmacokinetic enhancer, FB2001 exhibited plasma and lung drug concentration above the in vitro antiviral EC50 value.
  • No significant difference was observed between Chinese and American populations.

The results from the Phase 1 trial build on preclinical in vivo data of FB2001, where the drug was observed to reduce viral loads in both the lung and brain tissues of mice. Pharmacokinetic data obtained from preclinical studies showed significantly higher concentration of FB2001 in the lung compared to plasma. "FB2001 has demonstrated in vivo antiviral activity in the lung and brain tissue of SARS-CoV-2 mouse model without the need for pharmacokinetic boosting. Therefore, it holds great promise as a treatment for acute COVID-19 as well as long-COVID, both of which will be evaluated in further follow-up studies", said Dr Jay Lalezari, MD, Medical Director of Quest Clinical Research in San Francisco.

Poster presented at the 11th International Conference on Emerging Infectious Diseases (ICEID)

The current intravenous formulation of FB2001 is ideal for hospitalized patients with its rapid onset of action and is suited for patients with dysphagia or other problems with swallowing. Working with clinical research organizations, regional regulatory agencies, and local clinical centers, Frontier Biotechnologies has started a pivotal Phase 2/3 study (BRIGHT trial) to enroll about 1,200 hospitalized patients in hundreds of clinical centers worldwide. "The phase 1 data were really promising", said Dr Michael Hu, Chief Medical Officer of Frontier Biotechnologies, "and we are confident to carry out the pivotal trial to explore the utility of the drug in reducing the time to recovery in hospitalized patients due to COVID-19."

Frontier Biotechnologies is also developing a pulmonary formulation of FB2001 that could be used in out-patient setting for the treatment of mild Covid-19, as well as for post exposure prophylaxis. When inhaled directly into the respiratory tract and lungs, the tissue concentration of FB2001 is much higher than that in plasma; hence, the onset of action and viral clearance could potentially be faster than that of oral therapy.  

About Frontier Biotechnologies

Founded in 2013, Frontier Biotechnologies Inc. ("Frontier Biotech") is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness. Frontier Biotech is committed to discovering, development, manufacturing, and commercialization of innovative medicines that improve patient health.

More News by PR Newswire India

Automation Anywhere and the Center for Humanitarian Technology Launch 'Telegram for Humanity' Bot to Aid Refugees in Ukraine

Pomerantz Law Firm Opens London Office

Sphera Completes Previously Announced Acquisition of riskmethods, a Leader in Artificial Intelligence Supply Chain Risk Management Software

Hard Rock International Celebrates 23rd Annual PINKTOBER Campaign by Partnering with World-Renowned Chef Dominique Crenn

World's Fastest Growing Staking Service Provider Born out of Lugano, Switzerland

Firmenich Annual General Meeting 2022

Unispace: Data reveals Gen Z rely on the traditional office more than any other generation

Information Office of Beijing Municipal Government' Features: "My Beijing, My Story" Depicts the Lifestyle of People Living in Beijing

Automation Anywhere Unveils the Automation Success Platform with a Surge of Innovations

Deloitte Named a Leader in Worldwide Industry Cloud Professional Services by the IDC MarketScape

HAVAS HEALTH & YOU APPOINTS PAUL PFLEIDERER AS PRESIDENT OF HAVAS LIFE NEW YORK

Solace Launches Event Portal 2.0, Addressing the Biggest Challenges Enterprises Face in Designing, Managing and Governing Event-Driven Architecture at Scale

IMG Appoints Amanda Winkle as Chief Operating Officer

Vinco Ventures Announces Ross Miller as CEO and Settlement of Litigation

RevitaLash® Cosmetics Champions Breast Cancer Awareness, Research, and Support Worldwide with 2022 Pink Program Announcement

Aspire Academy and FIFA Kick Off the 8th Global Summit with high profile FIFA guests David Beckham and Wenger

EvolveWare Facilitates Non-disruptive Application Modernization with Industry's First and Only Agile Business Rules Extraction Solution

Stamus Networks Signs Reseller Agreement with EliteVAD

China Matters' Feature: How Does Basketball Shape Dongguan's Sports Culture?

Altair Presents Open, Flexible, and Scalable Total Digital Twin Solution

IZUMA NETWORKS ACQUIRES PELION'S DEVICE MANAGEMENT BUSINESS

Globalization Partners Rebrands as G-P and Reaffirms its Promise to Make a Global Workforce Possible for Growing Companies

Secureworks State of the Threat Report 2022: 52% of ransomware incidents over the past year started with compromise of unpatched remote services

First-of-its-kind government-industry partnership announced between Deakin University, Australia and Ministry of Education and Ministry of Skill Development and Entrepreneurship, Government of India

LyondellBasell Catalyst Production Expansion Adds Life to Infrastructure Projects

BE EVERYTHING - A new chapter opens in the story of United Colors of Benetton: new creative director, Andrea Incontri presents his first fashion show

PwC announces record global revenues of US$50 billion

Challenge the Highest Level of <MIR4>! A New Content, Hell Raid, Unveiled

Leading Gaming technology provider Quixant announces the launch of new cabinet offering

StoreHippo® launches Mystore Buyer and Seller Apps for ONDC

Cambrex Announces Stability Storage Expansions in Ireland and Belgium

TimesPro collaborates with IMT Hyderabad to launch programmes in Business & Retail Management

Industrial Transformation ASIA-PACIFIC 2022 returns to catalyse sustainable growth for advanced manufacturing in the region

The PI Group and Averna Announce their Partnership

Academic partnerships in focus, Global Education Summit commences at Chandigarh University

UST and Mendix Collaborate to Accelerate Low Code Development in Spain

Nestlé launches NESCAFÉ Plan 2030 to help drive regenerative agriculture, reduce greenhouse gas emissions and improve farmers' livelihoods

Ingenico Launches as Independent Company Following Acquisition by Apollo Private Equity Funds

Stockify announces single-window online service to buy unlisted equities

Manipal Hospital Whitefield's Exclusive Take on Minimally Invasive Advanced Surgical Procedures (MIAS)

THE LEELA PALACES, HOTELS AND RESORTS PARTNERS WITH RAJASTHAN POLO CLUB FOR ITS INAUGURAL SPONSORSHIP OF THE ROYAL SPORT IN INDIA

CLO Virtual Fashion Announces the Acquisition of GoVise Technologies

Education Cannot Wait Announces US$11.8 Million Catalytic Grant in Haiti

DXC Technology Calls for Latest Innovations from Insurance Startups and Scaleups across Asia Pacific through the DXC Invitational

Global AdTech Company TripleLift Names Dave Clark as New Chief Executive Officer

Navneeth Sulakhe joins Innoviti as Senior VP Human Resource Management

KEI Wires & Cables Hosts Real Kabbadi League Season 2

Automation Anywhere Secures $200 Million in Financing from Silicon Valley Bank and Hercules Capital

2022 World Trade Centers Association Member Forum Returns to New York City for First Time in Two Years

TATA POWER REINFORCES COMMITMENT TOWARDS GREEN ECOSYSTEM CONSERVATION ACROSS ITS RENEWABLE SITES

Azure Power wins the prestigious Golden Peacock Award for Sustainability

FANDOM ACQUIRES LEADING ENTERTAINMENT & GAMING BRANDS INCLUDING GAMESPOT, TV GUIDE AND METACRITIC

National Engineering Industries Ltd (NBC Bearings) honored with 'Iconic Brands of India 2022'

Celebrating Glorious 35 Years of BIMTECH

HABANOS, S.A. PRESENTED THE MONTECRISTO WIDE EDMUNDO IN WORLD PREMIERE IN SPAIN

Sanjay Ghodawat Foundation awarded The Mahatma Award 2022

STL announces Gram Galaxy - India's first integrated solution to connect villages with fibre

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Healthium Medtech amongst the first in Asia and first Indian Medtech Company to receive CE certification under the EU MDR (European Union Medical Device Regulation) norms for Class III implants

Jagadguru Kripalu Parishat holds Grand Rath Yatra on 3rd October 2022 near Kunda, Pratapgarh in honor of the 100th Birth Anniversary of Jagadguru Shri Kripalu Ji Maharaj

Addteq APAC Announces Rebranding, Changes Name to Enreap

Karwa Chauth 2022: FlowerAura Is All Geared Up To Enhance The Celebrations

DMCC AWARDED GLOBAL FREE ZONE OF THE YEAR FOR EIGHTH CONSECUTIVE YEAR

New Book Property Tax in Asia Provides the First Comprehensive Analysis of the Property Tax Across the World's Largest Continent

UN WOMEN'S HeForShe EXPANDS MOVEMENT THROUGH KEY PUBLIC AND PRIVATE PARTNERSHIPS IN EAST ASIA

STL unveils 5G cosmos to help Indian telcos fiberise their networks for 5G

STL launches Multiverse - India's first Multicore fibre and cable; aims to revolutionize the optical landscape

Tejas Networks successfully demonstrates end-to-end network based on its indigenous 4G/5G wireless, optical and satellite products

IIIT Hyderabad and Silicon Labs Launch Campus-wide Wi-SUN Network for Smart City Applications

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Fadnavis slams Nana Patole over his 'Che...
India logs 1,968 new COVID cases in last...
Be mindful of financial backgrounds, mor...
'What a disgrace': Mohandas Pai as B'lur...
Odisha: Dhamnagar bypoll scheduled for N...
Vijayan, Yechury, Karat, others break do...
More...    
 
 Top Stories
Centre designates Hizb-Ul-Mujahidee... 
Rs 26,000 crore to be spent on sett... 
CCI approves Sony-Zee merger with c... 
Rahul Gandhi condoles loss of lives... 
Kareena Kapoor shares warm birthday... 
Centre designates Hizb-Ul-Mujahidee... 
INS Tarkash completes Gulf of Guine... 
Endangerment of nuclear facilities ...